ENVUE MEDICAL INC (FEED)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$4.03+5.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · FEED
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Resolve Nasdaq listing issues related to the stock price to maintain listing status and investor confidence.
Newly stated in 2026-Q2. The Company received a Nasdaq Staff Determination Letter on July 10, 2026, due to the closing bid price being below $1.00 per share, risking delisting. This is a critical regulatory priority with no prior quarters stating it, and the situation reflects a regulatory compliance challenge.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Received a letter from Nasdaq notifying the Company that the closing bid price has been below $1.00 per share.”
Obtain and utilize a committed equity facility to strengthen the Company's capital position and support operations.
Newly stated in 2026-Q2. The Company secured a committed equity facility of up to $50 million as of August 12, 2026. This capital allocation priority is recent and shows a positive step to support liquidity and operations.
“Entered into a Common Shares Purchase Agreement with an institutional investor for a committed equity facility of up to $50 million.”
Focus on growing revenue and improving gross profit margins to enhance financial performance.
Stated as a priority in 8 of last 8 quarters. Revenue declined from $1,025,000 in 2025-Q1 to $239,000 in 2026-Q2, and gross profit shifted from a positive $369,000 to a loss of $266,000 over the same period. The trajectory shows declining revenue and margins, indicating limited progress on this priority.
“Revenue was $239,000 with a gross loss of $266,000, reflecting ongoing challenges in profitability.”
“Revenue was $653,000 with a gross loss of $55,000, showing some improvement over prior quarters.”
“Revenue was $312,000 with a gross loss of $370,000, indicating margin pressure.”
“Revenue was $722,000 with a gross profit of $189,000, a positive margin quarter.”
“Revenue was $494,000 with a gross loss of $35,000, showing margin challenges.”
“Revenue was $1,025,000 with a gross profit of $369,000, the highest revenue quarter in the period.”
“Revenue was $444,000 with a gross profit of $283,000, showing solid margins.”
“Revenue was $376,000 with a gross profit of $133,000, indicating positive margins.”
Focus on improving operating income and reducing net losses to enhance financial health.
Stated as a priority in 8 of last 8 quarters. Operating income declined from -$970,000 in 2024-Q3 to -$5,474,000 in 2026-Q2, and net income declined from -$998,000 to -$4,899,000 over the same period. The trajectory shows worsening losses, indicating limited progress on improving operating income and reducing net losses.
“Operating loss was $5,474,000 and net loss was $4,899,000, reflecting ongoing challenges.”
“Operating loss was $3,711,000 and net loss was $3,822,000, showing some worsening.”
“Operating loss was $14,814,000 and net loss was $12,852,000, a large loss quarter.”
“Operating loss was $2,247,000 with net income of $510,000, an unusual positive net income quarter.”
“Operating loss was $3,976,000 and net loss was $3,971,000, consistent losses.”
“Operating loss was $1,852,000 and net loss was $2,495,000, smaller losses earlier in the period.”
“Operating loss was $1,370,000 and net loss was $1,431,000, smaller losses.”
“Operating loss was $970,000 and net loss was $998,000, the smallest losses in the period.”
Over the trailing year it converted 0.87x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
35 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.